Labeler
UCB, Inc. NDC Codes
UCB, Inc. lists 45 finished drug products in the FDA NDC Directory under NDC labeler codes 0131, 43376, 50474.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Drugs
- Briviact, Neupro, Vimpat, Keppra, Bimzelx, Rystiggo, Cimzia, Zilbrysq, Keppra XR, Kygevvi, Fintepla, Nayzilam
- Active ingredients
- Levetiracetam, Brivaracetam, Rotigotine, Lacosamide, Bimekizumab, Rozanolixizumab, Zilucoplan, Certolizumab pegol, Doxecitine, Doxribtimine, Fenfluramine, Midazolam
- NDC labeler codes
- 0131, 43376, 50474
- Strengths
- Rozanolixizumab 140 mg/mL; Zilucoplan 40 mg/mL; Certolizumab pegol 200 mg/mL; Bimekizumab 320 mg/2mL; Bimekizumab 160 mg/mL; Lacosamide 10 mg/mL; Levetiracetam 750 mg/1; Levetiracetam 500 mg/1; Levetiracetam 100 mg/mL; Doxecitine 2 g/1; Doxribtimine 2 g/1; Fenfluramine 2.2 mg/mL; Midazolam 5 mg/.1mL; Brivaracetam 25 mg/1; Brivaracetam 50 mg/1; Brivaracetam 75 mg/1; Brivaracetam 100 mg/1; Brivaracetam 10 mg/mL; Brivaracetam 50 mg/5mL; Brivaracetam 10 mg/1
- Dosage forms
- Injection, Solution, Tablet, Film coated, Patch, Extended release, Solution, Kit, Tablet, Film coated, Extended release, Powder, For solution, Spray, Injection, Suspension, Injection, Injection, Solution, Concentrate
- Routes
- Oral, Subcutaneous, Transdermal, Intravenous, Nasal
- Drug classes (FDA established)
- Nonergot Dopamine Agonist, Neonatal Fc Receptor Blocker, Complement Inhibitor, Tumor Necrosis Factor Blocker, Benzodiazepine
- HCPCS / J-code
- None in Med-Code's directory for these products
- Package NDCs
- 74
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|
| Kygevvidoxecitine and doxribtimine | Doxecitine 2 g/1; Doxribtimine 2 g/1 | Powder, For solutionOral | 50474-350 | 50474-0350-30 | — |
| Cimziacertolizumab pegol | Certolizumab pegol 200 mg/mL | Injection, SolutionSubcutaneous | 50474-750 | 50474-0750-10 | — |
| Bimzelxbimekizumab | Bimekizumab 320 mg/2mL | Injection, SolutionSubcutaneous | 50474-782 | 50474-0782-8450474-0782-86 | — |
| Bimzelxbimekizumab | Bimekizumab 320 mg/2mL | Injection, SolutionSubcutaneous | 50474-783 | 50474-0783-78 | — |
| Rystiggorozanolixizumab | Rozanolixizumab 140 mg/mL | Injection, SolutionSubcutaneous | 50474-981 | 50474-0981-83 | — |
| Rystiggorozanolixizumab | Rozanolixizumab 140 mg/mL | Injection, SolutionSubcutaneous | 50474-982 | 50474-0982-84 | — |
| Rystiggorozanolixizumab | Rozanolixizumab 140 mg/mL | Injection, SolutionSubcutaneous | 50474-983 | 50474-0983-86 | — |
| Zilbrysqzilucoplan | Zilucoplan 40 mg/mL | Injection, SolutionSubcutaneous | 50474-990 | 50474-0990-80 | — |
| Zilbrysqzilucoplan | Zilucoplan 40 mg/mL | Injection, SolutionSubcutaneous | 50474-991 | 50474-0991-80 | — |
| Zilbrysqzilucoplan | Zilucoplan 40 mg/mL | Injection, SolutionSubcutaneous | 50474-992 | 50474-0992-80 | — |
| Bimzelxbimekizumab | Bimekizumab 160 mg/mL | Injection, SolutionSubcutaneous | 50474-780 | 50474-0780-7850474-0780-79 | — |
| Bimzelxbimekizumab | Bimekizumab 160 mg/mL | Injection, SolutionSubcutaneous | 50474-781 | 50474-0781-8450474-0781-8550474-0781-86+1 more | — |
| Rystiggorozanolixizumab | Rozanolixizumab 140 mg/mL | Injection, SolutionSubcutaneous | 50474-980 | 50474-0980-79 | — |
| Finteplafenfluramine | Fenfluramine 2.2 mg/mL | SolutionOral | 43376-322 | 43376-0322-3043376-0322-36 | — |
| Nayzilammidazolam | Midazolam 5 mg/.1mL | SprayNasal | 50474-500 | 50474-0500-15 | — |
| Briviactbrivaracetam | Brivaracetam 25 mg/1 | Tablet, Film coatedOral | 50474-470 | 50474-0470-0950474-0470-1450474-0470-66 | — |
| Briviactbrivaracetam | Brivaracetam 50 mg/1 | Tablet, Film coatedOral | 50474-570 | 50474-0570-0950474-0570-1450474-0570-66 | — |
| Briviactbrivaracetam | Brivaracetam 75 mg/1 | Tablet, Film coatedOral | 50474-670 | 50474-0670-66 | — |
| Briviactbrivaracetam | Brivaracetam 100 mg/1 | Tablet, Film coatedOral | 50474-770 | 50474-0770-0950474-0770-1450474-0770-66 | — |
| Briviactbrivaracetam | Brivaracetam 10 mg/mL | SolutionOral | 50474-870 | 50474-0870-15 | — |
| Briviactbrivaracetam | Brivaracetam 50 mg/5mL | Injection, SuspensionIntravenous | 50474-970 | 50474-0970-75 | — |
| Briviactbrivaracetam | Brivaracetam 10 mg/1 | Tablet, Film coatedOral | 50474-370 | 50474-0370-66 | — |
| Neuprorotigotine | Rotigotine 1 mg/24h | Patch, Extended releaseTransdermal | 50474-801 | 50474-0801-0350474-0801-17 | — |
| Neuprorotigotine | Rotigotine 2 mg/24h | Patch, Extended releaseTransdermal | 50474-802 | 50474-0802-0350474-0802-17 | — |
| Neuprorotigotine | Rotigotine 3 mg/24h | Patch, Extended releaseTransdermal | 50474-803 | 50474-0803-0350474-0803-17 | — |
| Neuprorotigotine | Rotigotine 4 mg/24h | Patch, Extended releaseTransdermal | 50474-804 | 50474-0804-0350474-0804-17 | — |
| Neuprorotigotine | Rotigotine 6 mg/24h | Patch, Extended releaseTransdermal | 50474-805 | 50474-0805-0350474-0805-17 | — |
| Neuprorotigotine | Rotigotine 8 mg/24h | Patch, Extended releaseTransdermal | 50474-806 | 50474-0806-0350474-0806-17 | — |
| Neuprorotigotine | — | Kit | 50474-808 | 50474-0808-11 | — |
| Vimpatlacosamide | Lacosamide 10 mg/mL | SolutionOral | 0131-5410 | 00131-5410-72 | — |
| Vimpatlacosamide | Lacosamide 10 mg/mL | InjectionIntravenous | 0131-1810 | 00131-1810-67 | — |
| Vimpatlacosamide | Lacosamide 50 mg/1 | Tablet, Film coatedOral | 0131-2477 | 00131-2477-3500131-2477-6000131-2477-99 | — |
| Vimpatlacosamide | Lacosamide 100 mg/1 | Tablet, Film coatedOral | 0131-2478 | 00131-2478-3500131-2478-6000131-2478-99 | — |
| Vimpatlacosamide | Lacosamide 150 mg/1 | Tablet, Film coatedOral | 0131-2479 | 00131-2479-3500131-2479-6000131-2479-99 | — |
| Vimpatlacosamide | Lacosamide 200 mg/1 | Tablet, Film coatedOral | 0131-2480 | 00131-2480-3500131-2480-6000131-2480-99 | — |
| Cimziacertolizumab pegol | Certolizumab pegol 200 mg/mL | Injection, SolutionSubcutaneous | 50474-710 | 50474-0710-7950474-0710-8050474-0710-81 | — |
| Keppra XRlevetiracetam | Levetiracetam 750 mg/1 | Tablet, Film coated, Extended releaseOral | 50474-599 | 50474-0599-66 | — |
| Keppra XRlevetiracetam | Levetiracetam 500 mg/1 | Tablet, Film coated, Extended releaseOral | 50474-598 | 50474-0598-66 | — |
| Cimziacertolizumab pegol | — | Kit | 50474-700 | 50474-0700-6150474-0700-62 | — |
| Keppralevetiracetam | Levetiracetam 100 mg/mL | Injection, Solution, ConcentrateIntravenous | 50474-002 | 50474-0002-63 | — |
| Keppralevetiracetam | Levetiracetam 100 mg/mL | SolutionOral | 50474-001 | 50474-0001-48 | — |
| Keppralevetiracetam | Levetiracetam 250 mg/1 | Tablet, Film coatedOral | 50474-594 | 50474-0594-40 | — |
| Keppralevetiracetam | Levetiracetam 500 mg/1 | Tablet, Film coatedOral | 50474-595 | 50474-0595-40 | — |
| Keppralevetiracetam | Levetiracetam 750 mg/1 | Tablet, Film coatedOral | 50474-596 | 50474-0596-40 | — |
| Keppralevetiracetam | Levetiracetam 1000 mg/1 | Tablet, Film coatedOral | 50474-597 | 50474-0597-66 | — |
UCB, Inc.: common questions
- What is UCB, Inc.'s NDC labeler code?
- 0131, 43376, 50474. The labeler code is the first segment of each NDC. About labeler codes.
- Is there a J-code for UCB, Inc.?
- Med-Code's curated HCPCS directory has no drug-specific code for these products. Drugs dispensed by a pharmacy are billed by NDC. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.